30 results about "Echovirus" patented technology

There are provided methods for treatment of abnormal cells such as cancer cells in a mammal. The methods involve treating the mammal with virus selected from echoviruses and modified forms and combination thereof, which recognize α2β1 for infectivity of the cells. There are also provided methods for screening viruses for use in a method of the invention as well as pharmaceutical compositions for use in the methods.

The invention relates to the field of virus and the field of tumor treatment. Concretely, the invention relates to ECHO 25 or a modified form thereof, or a genomic sequence or cDNA sequence comprisingthe ECHO 25 or the modified form of the ECHO 25, or nucleic acid molecules of a complementary sequences of the genomic sequence or cDNA sequence, applications in treating tumors for a subject such asa human being, and applications in preparing pharmaceutical compositions for treating the tumors for the subject such as a human being. The invention also relates to a method for treating the tumors.The method includes steps of applying the ECHO 25 or the modified form of the ECHO 25, or the genomic sequence or cDNA sequence comprising the ECHO 25 or the modified form of the ECHO 25 or the nucleic acid molecules of the complementary sequences of the genomic sequence or cDNA sequence to the subject who needs the treatment.

This invention discloses a method for preparing ECHO virus type 30 VP. The method comprises: (1) performing trizol decomposition and extraction of ECHO virus type 30 to obtain VP mRNA, performing reverse transcription to obtain VP cDNA, amplifying by PCR, purifying and cutting with enzyme to obtain Pet41a+VP; (2) transferring to Escherichia coli DH5a, amplifying, extracting and purifying to obtain recombinant plasmid with right sequence; (3) transferring to BL21 (DE3) bacterium, and expressing recombinant protein at 30 deg.C and 0.1mM IPTG; (4) culturing the activated strains of recombinant protein, fermenting at a high density, and inducing in low-oxygen condition, decomposing the bacterium obtained, and dissolving the inclusion body and purifying; (5) inspecting by immunoassay or bioactivity detection, and collecting purified ECHO virus type 30 VP.

The invention discloses new application of scullcapflavone in preparing a medicament for treating enterovirus infection, in particular new application of scullcapflavone in preparing a medicament for treating or preventing a hand-foot-and-mouth disease caused by enterovirus infection. The scullcapflavone comprises an extract of baicalein, baicalin or scutellaria baicalensis general flavone; and the enterovirus indicates a coxsackie virus A group, a coxsackie virus B group, echovirus or enterovirus EV71 which causes the hand-foot-and-mouth disease. The scullcapflavone as an active substance ismixed with a pharmaceutically allowable excipient and made into a preparation which can be accepted by a patient and can be used for treating and preventing the hand-foot-and-mouth disease by injection administration, mucosa administration, oral administration or inhalation and has obvious treating effect and high safety.

The invention discloses a traditional Chinese medicine composition for treating respiratory tract viral infectious diseases and a preparation method thereof. The composition comprises the following active pharmaceutical ingredients in parts by weight: 5-25g of perilla leaf, 5-25g of tatarian aster root, 5-25g of Chinese thorowax root, 5-25g of schizonepeta spike, 5-25g of great burdock achene, 5-25g of apricot seed and 1-15g of liquoric root. The active pharmaceutical ingredients can be matched with excipients and a flavoring agent to be directly or indirectly prepared into pharmaceutically acceptable capsules, oral liquid, granules, syrup, tablets, effervescent particles, dropping pills, aerosol, spraying agent, gargle, mouthwash and a variety of formulations via conventional process steps. The traditional Chinese medicine composition can be clinically used for treating or preventing the respiratory tract viral infectious diseases caused by influenza A virus, influenza B virus, rhino virus, coronavirus, respiratory syncytial virus, adenovirus, parainfluenza virus, enteric cytopathogenichuman orphan virus, Coxsackie virus and the like.

The invention provides echovirus type-9 VP1 protein specific antigen epitope and a preparation method and application of a fusion protein thereof, and relates to the fields of genetic engineering technology, vaccines and diagnostic reagents. Computer analysis is carried out on the amino acid sequence of the echovirus type-9 surface protein VP1 to screen out protein fragments containing strong specific antigen epitope, namely 75th amino acid-102nd amino acid, 127th amino acid-140th amino acid, 204th amino acid-237th amino acid and 257th amino acid-300th amino acid, and the four protein fragments are connected through two glycines and one serine to form one antigen epitope fusion protein. Codons preferred by both eukaryon and prokaryote are selected for chemical synthesis of a brand new gene sequence of the antigen epitope fusion protein, the genetic engineering technology is utilized to prepare the antigen epitope fusion protein of the echovirus type-9 VP1 protein by expression, and the antigen epitope fusion protein is used for developing an echovirus antibody detection kit and preparing echovirus monoclonal antibody and polyclonal antibody.

The present invention relates to a novel compound, a pharmaceutically acceptable salt or an optical isomer thereof, a method for preparing them, and a pharmaceutical composition for preventing or treating viral diseases containing them as active ingredients. The novel compounds according to the present invention not only have low cytotoxicity, but also have excellent antiviral activity against picornaviruses including coxsackieviruses, enteroviruses, echoviruses, polioviruses and rhinoviruses, therefore It can be used as a pharmaceutical composition for the prevention or treatment of viral diseases such as poliomyelitis, acute hemorrhagic conjunctivitis, viral meningitis, hand, foot and mouth disease, blister disease, hepatitis A, myositis, Myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpetic angina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The invention discloses an enteric cytopathogenic human orphan virus 6-type VP1 protein specific epitope, a fusion protein of the enteric cytopathogenic human orphan virus 6-type VP1 protein specific epitope and a preparation method and use of the fusion protein and relates to the field of a gene engineering technology, a vaccine and a diagnostic reagent. The preparation method comprises analyzing an enteric cytopathogenic human orphan virus 6-type surface protein VP1 amino acid sequence by a computer, and screening strong specific epitope-containing protein fragments comprising 75th-101th amino acids, 127th-141th amino acids, 204th-237th amino acids and 257th-289th amino acids, wherein the four protein fragments are connected by 2 glycines and 1 serine so that the epitope fusion protein is formed. A codon in favor with eucaryotes and prokaryotes is used, a brand new gene sequence of the epitope fusion protein is chemically synthesized, through a gene engineering technology, the enteric cytopathogenic human orphan virus 6-type VP1 protein epitope fusion protein is expressed and prepared and is used for development of an enteric cytopathogenic human orphan virus antibody detection reagent and preparation of an enteric cytopathogenic human orphan virus monoclonal antibody and polyclonal antibody.